ABSTRACT

Handling of dyslipidemia in Indonesia generally uses statin drugs, one of which is simvastatin.
This study was designed to analyze the cost effectiveness of the treatment of dyslipidemia using
simvastatin 10 mg or 20 mg in the Madani Hospital of Palu in November 2018-March 2019
based on ACER value (Average Cost Effectiveness Ratio) and ICER (Incremental Cost
Effectiveness Ratio). The method used was descriptive which was done prospectively with a
total sample of 30 and collected secondary data in the form of lipid profiles namely total
cholesterol, triglycerides, LDL, HDL levels from baseline to evaluation for 4 weeks, and
collecting data on patients' immediate medical costs. The results showed that the ACER value
based on the effectiveness of total cholesterol reduction was simvastatin 20 mg Rp. 131,230.8,
for LDL reduction is simvastatin 20 mg Rp.122,438.3, for increasing HDL is simvastatin 10 mg
Rp.123,440.7 and decreasing triglycerides is simvastatin 20 mg Rp.122,438.3 and for ICER
values for HDL increase of Rp. .1,877.2. It can be concluded that the most cost effective based
on the ACER value for the effectiveness of total cholesterol, triglycerides and LDL is
simvastatin 20 mg while for HDL is simvastatin 10 mg..

Keywords: cost effectiveness , simvastatin 10 mg and 20 mg , dyslipidemia, ACER, ICER